The higher barrier of darunavir and tipranavir resistance for HIV-1 protease
- 9 September 2011
- journal article
- research article
- Published by Elsevier BV in Biochemical and Biophysical Research Communications
- Vol. 412 (4), 737-742
- https://doi.org/10.1016/j.bbrc.2011.08.045
Abstract
No abstract availableKeywords
Funding Information
- Michigan Economic Development Corporation and the Michigan Technology Tri-Corridor (085P1000817)
This publication has 23 references indexed in Scilit:
- Contribution of the 80s loop of HIV-1 protease to the multidrug-resistance mechanism: crystallographic study of MDR769 HIV-1 protease variantsActa Crystallographica Section D-Structural Biology, 2011
- HIV-1 Protease Mutations and Protease Inhibitor Cross-ResistanceAntimicrobial Agents and Chemotherapy, 2010
- Design Parameters to Control Synthetic Gene Expression in Escherichia coliPLOS ONE, 2009
- Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIVBioorganic & Medicinal Chemistry, 2007
- Rationale and Uses of a Public HIV Drug‐Resistance DatabaseThe Journal of Infectious Diseases, 2006
- Web Resources for HIV Type 1 Genotypic-Resistance Test InterpretationClinical Infectious Diseases, 2006
- Coot: model-building tools for molecular graphicsActa Crystallographica Section D-Biological Crystallography, 2004
- High Resolution Crystal Structures of HIV-1 Protease with a Potent Non-peptide Inhibitor (UIC-94017) Active Against Multi-drug-resistant Clinical StrainsJournal of Molecular Biology, 2004
- [20] Processing of X-ray diffraction data collected in oscillation modeMethods in Enzymology, 1997
- The CCP4 suite: programs for protein crystallographyActa Crystallographica Section D-Biological Crystallography, 1994